IMPORTANCE: Cerebral microbleeds (CMBs) are collections of blood breakdown products that are a common incidental finding in magnetic resonance imaging of elderly individuals. Cerebral microbleeds are associated with cognitive deficits, but the mechanism is unclear. Studies show that individuals with CMBs related to symptomatic cerebral amyloid angiopathy have abnormal vascular reactivity and cerebral blood flow (CBF), but, to our knowledge, abnormalities in cerebral blood flow have not been reported for healthy individuals with incidental CMBs. OBJECTIVE: To evaluate the association of incidental CMBs with resting-state CBF, cerebral metabolism, cerebrovascular disease, β-amyloid (Aβ), and cognition. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study of 55 cognitively normal individuals with a mean (SD) age of 86.8 (2.7) years was conducted from May 1, 2010, to May 1, 2013, in an academic medical center in Pittsburgh; data analysis was performed between June 10, 2013, and April 9, 2015. INTERVENTIONS: 3-Tesla magnetic resonance imaging was performed with susceptibility-weighted imaging or gradient-recalled echo to assess CMBs, arterial spin labeling for CBF, and T1- and T2-weighted imaging for atrophy, white matter hyperintensities, and infarcts. Positron emission tomography was conducted with fluorodeoxyglucose to measure cerebral metabolism and Pittsburgh compound B for fibrillar Aβ. Neuropsychological evaluation, including the Clinical Dementia Rating scale, was performed. MAIN OUTCOMES AND MEASURES: Magnetic resonance images were rated for the presence and location of CMBs. Lobar CMBs were subclassified as cortical or subcortical. Measurements of CBF, metabolism, and Aβ were compared with the presence and number of CMBs with voxelwise and region-of-interest analyses. RESULTS: The presence of cortical CMBs was associated with significantly reduced CBF in multiple regions on voxelwise and region-of-interest analyses (percentage difference in global CBF, -25.3%; P = .0003), with the largest reductions in the parietal cortex (-37.6%; P < .0001) and precuneus (-31.8%; P = .0006). Participants with any CMBs showed a nonsignificant trend toward reduced CBF. Participants with cortical CMBs had a significant association with greater prevalence of infarcts (24% vs 6%; P = .047) and demonstrated a trend to greater prevalence of deficits demonstrated on the Clinical Dementia Rating scale (45% vs 19%; P = .12). There was no difference in cortical amyloid (measured by Pittsburgh compound B positron emission tomography) between participants with and without CMBs (P = .60). CONCLUSIONS AND RELEVANCE: In cognitively normal elderly individuals, incidental CMBs in cortical locations are associated with widespread reductions in resting-state CBF. Chronic hypoperfusion may put these people at risk for neuronal injury and neurodegeneration. Our results suggest that resting-state CBF is a marker of CMB-related small-vessel disease.
IMPORTANCE: Cerebral microbleeds (CMBs) are collections of blood breakdown products that are a common incidental finding in magnetic resonance imaging of elderly individuals. Cerebral microbleeds are associated with cognitive deficits, but the mechanism is unclear. Studies show that individuals with CMBs related to symptomatic cerebral amyloid angiopathy have abnormal vascular reactivity and cerebral blood flow (CBF), but, to our knowledge, abnormalities in cerebral blood flow have not been reported for healthy individuals with incidental CMBs. OBJECTIVE: To evaluate the association of incidental CMBs with resting-state CBF, cerebral metabolism, cerebrovascular disease, β-amyloid (Aβ), and cognition. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study of 55 cognitively normal individuals with a mean (SD) age of 86.8 (2.7) years was conducted from May 1, 2010, to May 1, 2013, in an academic medical center in Pittsburgh; data analysis was performed between June 10, 2013, and April 9, 2015. INTERVENTIONS: 3-Tesla magnetic resonance imaging was performed with susceptibility-weighted imaging or gradient-recalled echo to assess CMBs, arterial spin labeling for CBF, and T1- and T2-weighted imaging for atrophy, white matter hyperintensities, and infarcts. Positron emission tomography was conducted with fluorodeoxyglucose to measure cerebral metabolism and Pittsburgh compound B for fibrillar Aβ. Neuropsychological evaluation, including the Clinical Dementia Rating scale, was performed. MAIN OUTCOMES AND MEASURES: Magnetic resonance images were rated for the presence and location of CMBs. Lobar CMBs were subclassified as cortical or subcortical. Measurements of CBF, metabolism, and Aβ were compared with the presence and number of CMBs with voxelwise and region-of-interest analyses. RESULTS: The presence of cortical CMBs was associated with significantly reduced CBF in multiple regions on voxelwise and region-of-interest analyses (percentage difference in global CBF, -25.3%; P = .0003), with the largest reductions in the parietal cortex (-37.6%; P < .0001) and precuneus (-31.8%; P = .0006). Participants with any CMBs showed a nonsignificant trend toward reduced CBF. Participants with cortical CMBs had a significant association with greater prevalence of infarcts (24% vs 6%; P = .047) and demonstrated a trend to greater prevalence of deficits demonstrated on the Clinical Dementia Rating scale (45% vs 19%; P = .12). There was no difference in cortical amyloid (measured by Pittsburgh compound B positron emission tomography) between participants with and without CMBs (P = .60). CONCLUSIONS AND RELEVANCE: In cognitively normal elderly individuals, incidental CMBs in cortical locations are associated with widespread reductions in resting-state CBF. Chronic hypoperfusion may put these people at risk for neuronal injury and neurodegeneration. Our results suggest that resting-state CBF is a marker of CMB-related small-vessel disease.
Authors: Andrew Dumas; Gregory A Dierksen; M Edip Gurol; Amy Halpin; Sergi Martinez-Ramirez; Kristin Schwab; Jonathan Rosand; Anand Viswanathan; David H Salat; Jonathan R Polimeni; Steven M Greenberg Journal: Ann Neurol Date: 2012-07 Impact factor: 10.422
Authors: Annelies E van der Vlies; Jeroen D C Goos; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier Journal: Neurology Date: 2012-08-08 Impact factor: 9.910
Authors: M Edip Gurol; Gregory Dierksen; Rebecca Betensky; Christopher Gidicsin; Amy Halpin; Alex Becker; Jeremy Carmasin; Alison Ayres; Kristin Schwab; Anand Viswanathan; David Salat; Jonathan Rosand; Keith A Johnson; Steven M Greenberg Journal: Neurology Date: 2012-07-11 Impact factor: 9.910
Authors: Stefano Peca; Cheryl R McCreary; Emily Donaldson; Gopukumar Kumarpillai; Nandavar Shobha; Karla Sanchez; Anna Charlton; Craig D Steinback; Andrew E Beaudin; Daniela Flück; Neelan Pillay; Gordon H Fick; Marc J Poulin; Richard Frayne; Bradley G Goodyear; Eric E Smith Journal: Neurology Date: 2013-10-04 Impact factor: 9.910
Authors: F Fazekas; R Kleinert; G Roob; G Kleinert; P Kapeller; R Schmidt; H P Hartung Journal: AJNR Am J Neuroradiol Date: 1999-04 Impact factor: 3.825
Authors: Wolff Kirsch; Grant McAuley; Barbara Holshouser; Floyd Petersen; Muhammad Ayaz; Harry V Vinters; Cindy Dickson; E Mark Haacke; William Britt; James Larseng; Ivan Kim; Claudius Mueller; Matthew Schrag; Daniel Kido Journal: J Alzheimers Dis Date: 2009 Impact factor: 4.472
Authors: M W Vernooij; A van der Lugt; M A Ikram; P A Wielopolski; W J Niessen; A Hofman; G P Krestin; M M B Breteler Journal: Neurology Date: 2008-04-01 Impact factor: 9.910
Authors: Timothy M Hughes; Lewis H Kuller; Emma J M Barinas-Mitchell; Rachel H Mackey; Eric M McDade; William E Klunk; Howard J Aizenstein; Ann D Cohen; Beth E Snitz; Chester A Mathis; Steven T Dekosky; Oscar L Lopez Journal: Neurology Date: 2013-10-16 Impact factor: 9.910
Authors: Jie Ding; Sigurður Sigurðsson; Pálmi V Jónsson; Gudny Eiriksdottir; Andreas Charidimou; Oscar L Lopez; Mark A van Buchem; Vilmundur Guðnason; Lenore J Launer Journal: JAMA Neurol Date: 2017-09-01 Impact factor: 18.302
Authors: Rebecca J Williams; Bradley G Goodyear; Stefano Peca; Cheryl R McCreary; Richard Frayne; Eric E Smith; G Bruce Pike Journal: J Cereb Blood Flow Metab Date: 2017-02-01 Impact factor: 6.200
Authors: Jonathan Graff-Radford; Eider M Arenaza-Urquijo; David S Knopman; Christopher G Schwarz; Robert D Brown; Alejandro A Rabinstein; Jeffrey L Gunter; Matthew L Senjem; Scott A Przybelski; Timothy Lesnick; Chadwick Ward; Michelle M Mielke; Val J Lowe; Ronald C Petersen; Walter K Kremers; Kejal Kantarci; Clifford R Jack; Prashanthi Vemuri Journal: Brain Date: 2019-08-01 Impact factor: 13.501
Authors: Mafalda Cacciottolo; Amy Christensen; Alexandra Moser; Jiahui Liu; Christian J Pike; Conor Smith; Mary Jo LaDu; Patrick M Sullivan; Todd E Morgan; Egor Dolzhenko; Andreas Charidimou; Lars-Olof Wahlund; Maria Kristofferson Wiberg; Sara Shams; Gloria Chia-Yi Chiang; Caleb E Finch Journal: Neurobiol Aging Date: 2015-10-19 Impact factor: 4.673
Authors: Panagiotis Fotiadis; Sanneke van Rooden; Jeroen van der Grond; Aaron Schultz; Sergi Martinez-Ramirez; Eitan Auriel; Yael Reijmer; Anna M van Opstal; Alison Ayres; Kristin M Schwab; Trey Hedden; Jonathan Rosand; Anand Viswanathan; Marieke Wermer; Gisela Terwindt; Reisa A Sperling; Jonathan R Polimeni; Keith A Johnson; Mark A van Buchem; Steven M Greenberg; M Edip Gurol Journal: Lancet Neurol Date: 2016-05-11 Impact factor: 44.182
Authors: Margarita Abi Zeid Daou; Brian D Boyd; Manus J Donahue; Kimberly Albert; Warren D Taylor Journal: J Psychiatr Res Date: 2017-11-11 Impact factor: 4.791